Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Merck KGaA price target lowered to EUR 200 from EUR 208 at Credit Suisse » 15:36
05/13/22
05/13
15:36
05/13/22
15:36
MKKGY

Merck KGaA

$33.31 /

-1.765 (-5.03%)

Credit Suisse analyst…

Credit Suisse analyst Trung Huynh lowered the firm's price target on Merck KGaA to EUR 200 from EUR 208 and keeps an Outperform rating on the shares.

ShowHide Related Items >><<
MKKGY Merck KGaA
$33.31 /

-1.765 (-5.03%)

MKKGY Merck KGaA
$33.31 /

-1.765 (-5.03%)

04/29/22 Morgan Stanley
Merck KGaA price target raised to EUR 225 from EUR 220 at Morgan Stanley
04/04/22 Morgan Stanley
Merck KGaA price target lowered to EUR 220 from EUR 230 at Morgan Stanley
01/04/22 JPMorgan
Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan
09/17/21 Morgan Stanley
Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
Recommendations
Merck KGaA price target raised to EUR 225 from EUR 220 at Morgan Stanley » 14:23
04/29/22
04/29
14:23
04/29/22
14:23
MKKGY

Merck KGaA

$36.56 /

+0.71 (+1.98%)

Morgan Stanley analyst…

Morgan Stanley analyst Mark Purcell raised the firm's price target on Merck KGaA to EUR 225 from EUR 220 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
MKKGY Merck KGaA
$36.56 /

+0.71 (+1.98%)

MKKGY Merck KGaA
$36.56 /

+0.71 (+1.98%)

04/04/22 Morgan Stanley
Merck KGaA price target lowered to EUR 220 from EUR 230 at Morgan Stanley
01/04/22 JPMorgan
Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan
09/17/21 Morgan Stanley
Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
09/13/21 Deutsche Bank
Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
Over a month ago
Recommendations
Merck KGaA price target lowered to EUR 220 from EUR 230 at Morgan Stanley » 14:16
04/04/22
04/04
14:16
04/04/22
14:16
MKKGY

Merck KGaA

$42.22 /

+0.41 (+0.98%)

Morgan Stanley analyst…

Morgan Stanley analyst Mark Purcell lowered the firm's price target on Merck KGaA to EUR 220 from EUR 230 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
MKKGY Merck KGaA
$42.22 /

+0.41 (+0.98%)

MKKGY Merck KGaA
$42.22 /

+0.41 (+0.98%)

01/04/22 JPMorgan
Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan
09/17/21 Morgan Stanley
Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
09/13/21 Deutsche Bank
Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
09/10/21 JPMorgan
Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
Over a quarter ago
Hot Stocks
F-star Therapeutics announces Merck KGaA exercises fourth licensing option » 08:07
01/05/22
01/05
08:07
01/05/22
08:07
FSTX

F-star Therapeutics

$4.96 /

-0.44 (-8.15%)

, MKKGY

Merck KGaA

$49.71 /

-0.74 (-1.47%)

F-star Therapeutics…

F-star Therapeutics (FSTX) announced that Ares Trading, an affiliate of Merck KGaA (MKKGY), Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration. Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will be responsible for all future development and commercialization costs and will pay future success-based milestones and royalties on any net sales, resulting from programs covered by the agreement. Eliot Forster, CEO of F-star Therapeutics, Inc, said: "We were delighted to see the recent data presented by Merck KGaA, Darmstadt, Germany, from our long-standing collaboration at the recent SITC conference, demonstrating the unique potential of the F-star bispecific platform. This latest licensing option marks another positive milestone in our collaboration and it is exciting to see our partner successfully progress another mAb2 based program. Along with our internal pipeline, we believe all of these next generation immuno-oncology programs will make a real difference to the lives of patients with cancer."

ShowHide Related Items >><<
FSTX F-star Therapeutics
$4.96 /

-0.44 (-8.15%)

FSTX F-star Therapeutics
$4.96 /

-0.44 (-8.15%)

11/18/21 Ladenburg
F-star Therapeutics price target lowered to $15 from $27 at Ladenburg
11/12/21 Oppenheimer
F-star Therapeutics price target raised to $33 from $30 at Oppenheimer
07/08/21 SVB Leerink
F-star Therapeutics initiated with an Outperform at SVB Leerink
06/09/21 B. Riley
B. Riley starts F-star Therapeutics at Buy, sees 307% potential upside
MKKGY Merck KGaA
$49.71 /

-0.74 (-1.47%)

01/04/22 JPMorgan
Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan
09/17/21 Morgan Stanley
Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
09/13/21 Deutsche Bank
Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
09/10/21 JPMorgan
Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
FSTX F-star Therapeutics
$4.96 /

-0.44 (-8.15%)

  • 09
    May
Recommendations
Merck KGaA price target raised to EUR 270 from EUR 245 at JPMorgan » 14:39
01/04/22
01/04
14:39
01/04/22
14:39
MKKGY

Merck KGaA

$50.45 /

-1.65 (-3.17%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Merck KGaA to EUR 270 from EUR 245 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
MKKGY Merck KGaA
$50.45 /

-1.65 (-3.17%)

09/17/21 Morgan Stanley
Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
09/13/21 Deutsche Bank
Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
09/10/21 JPMorgan
Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
09/02/21 Barclays
Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
Conference/Events
Stifel healthcare analysts to hold an analyst/industry conference call » 14:25
10/14/21
10/14
14:25
10/14/21
14:25
TPTX

Turning Point Therapeutics

$49.07 /

+2.065 (+4.39%)

, RHHBY

Roche

$48.22 /

-0.01 (-0.02%)

, NVS

Novartis

$82.57 /

+0.105 (+0.13%)

, MKKGY

Merck KGaA

$44.51 /

+1.15 (+2.65%)

, MRTX

Mirati Therapeutics

$176.55 /

+4.72 (+2.75%)

, AMGN

Amgen

$207.22 /

+3.73 (+1.83%)

, RVMD

Revolution Medicines

$28.65 /

+0.79 (+2.84%)

Healthcare Analysts,…

Healthcare Analysts, along with Dr. David Ross Camidge and Dr. Vamsidhar Velcheti, discuss how TPTX's repotrectinib safety data might inform 1L or 2L market share in ROS1+ NSCLC, the opportunity for TPTX's TPX-022 MET inhibitor in METex14 NSCLC and Amgen's Lumakras KRAS G12C NSCLC launch on an Analyst/Industry conference call to be held on October 14 at 3 pm. Webcast Link

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$49.07 /

+2.065 (+4.39%)

RVMD Revolution Medicines
$28.65 /

+0.79 (+2.84%)

RHHBY Roche
$48.22 /

-0.01 (-0.02%)

NVS Novartis
$82.57 /

+0.105 (+0.13%)

MRTX Mirati Therapeutics
$176.55 /

+4.72 (+2.75%)

MKKGY Merck KGaA
$44.51 /

+1.15 (+2.65%)

AMGN Amgen
$207.22 /

+3.73 (+1.83%)

TPTX Turning Point Therapeutics
$49.07 /

+2.065 (+4.39%)

10/12/21 H.C. Wainwright
Turning Point price target lowered to $162 from $178 at H.C. Wainwright
10/11/21 JMP Securities
Turning Point downgraded to Market Perform from Outperform at JMP Securities
10/08/21 Roth Capital
Turning Point selloff brings 'bargain value,' says Roth Capital
10/08/21 Wedbush
Turning Point Therapeutics price target lowered to $125 from $166 at Wedbush
RHHBY Roche
$48.22 /

-0.01 (-0.02%)

10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
NVS Novartis
$82.57 /

+0.105 (+0.13%)

10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
10/08/21 UBS
Novartis price target lowered to CHF 92 from CHF 95 at UBS
09/29/21 Stifel
Blueprint Medicines rersumed with a Hold at Stifel
09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
MKKGY Merck KGaA
$44.51 /

+1.15 (+2.65%)

09/17/21 Morgan Stanley
Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
09/13/21 Deutsche Bank
Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
09/10/21 JPMorgan
Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
09/02/21 Barclays
Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
MRTX Mirati Therapeutics
$176.55 /

+4.72 (+2.75%)

09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
09/21/21 Oppenheimer
Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer
09/07/21 JPMorgan
Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan
AMGN Amgen
$207.22 /

+3.73 (+1.83%)

10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
RVMD Revolution Medicines
$28.65 /

+0.79 (+2.84%)

09/22/21 Stifel
Revolution Medicines initiated with a Hold at Stifel
08/17/21 H.C. Wainwright
Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright
08/12/21
Fly Intel: Top five analyst downgrades
08/12/21 Guggenheim
Revolution Medicines price target lowered to $34 from $52 at Guggenheim
TPTX Turning Point Therapeutics
$49.07 /

+2.065 (+4.39%)

RVMD Revolution Medicines
$28.65 /

+0.79 (+2.84%)

RHHBY Roche
$48.22 /

-0.01 (-0.02%)

NVS Novartis
$82.57 /

+0.105 (+0.13%)

MRTX Mirati Therapeutics
$176.55 /

+4.72 (+2.75%)

AMGN Amgen
$207.22 /

+3.73 (+1.83%)

  • 04
    Feb
  • 28
    Oct
  • 27
    Oct
RHHBY Roche
$48.22 /

-0.01 (-0.02%)

NVS Novartis
$82.57 /

+0.105 (+0.13%)

RHHBY Roche
$48.22 /

-0.01 (-0.02%)

NVS Novartis
$82.57 /

+0.105 (+0.13%)

MRTX Mirati Therapeutics
$176.55 /

+4.72 (+2.75%)

AMGN Amgen
$207.22 /

+3.73 (+1.83%)

NVS Novartis
$82.57 /

+0.105 (+0.13%)

AMGN Amgen
$207.22 /

+3.73 (+1.83%)

Conference/Events
Stifel healthcare analysts to hold an analyst/industry conference call » 04:55
10/14/21
10/14
04:55
10/14/21
04:55
TPTX

Turning Point Therapeutics

$47.00 /

+0.9 (+1.95%)

, RHHBY

Roche

$48.22 /

-0.01 (-0.02%)

, NVS

Novartis

$82.47 /

+0.425 (+0.52%)

, MKKGY

Merck KGaA

$44.51 /

+1.15 (+2.65%)

, MRTX

Mirati Therapeutics

$171.89 /

-6.27 (-3.52%)

, AMGN

Amgen

$203.70 /

+1.63 (+0.81%)

, RVMD

Revolution Medicines

$27.77 /

+0.385 (+1.41%)

Healthcare Analysts,…

Healthcare Analysts, along with Dr. David Ross Camidge and Dr. Vamsidhar Velcheti, discuss how TPTX's repotrectinib safety data might inform 1L or 2L market share in ROS1+ NSCLC, the opportunity for TPTX's TPX-022 MET inhibitor in METex14 NSCLC and Amgen's Lumakras KRAS G12C NSCLC launch on an Analyst/Industry conference call to be held on October 14 at 3 pm. Webcast Link

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$47.00 /

+0.9 (+1.95%)

RVMD Revolution Medicines
$27.77 /

+0.385 (+1.41%)

RHHBY Roche
$48.22 /

-0.01 (-0.02%)

NVS Novartis
$82.47 /

+0.425 (+0.52%)

MRTX Mirati Therapeutics
$171.89 /

-6.27 (-3.52%)

MKKGY Merck KGaA
$44.51 /

+1.15 (+2.65%)

AMGN Amgen
$203.70 /

+1.63 (+0.81%)

TPTX Turning Point Therapeutics
$47.00 /

+0.9 (+1.95%)

10/12/21 H.C. Wainwright
Turning Point price target lowered to $162 from $178 at H.C. Wainwright
10/11/21 JMP Securities
Turning Point downgraded to Market Perform from Outperform at JMP Securities
10/08/21 Roth Capital
Turning Point selloff brings 'bargain value,' says Roth Capital
10/08/21 Wedbush
Turning Point Therapeutics price target lowered to $125 from $166 at Wedbush
RHHBY Roche
$48.22 /

-0.01 (-0.02%)

10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
NVS Novartis
$82.47 /

+0.425 (+0.52%)

10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
10/08/21 UBS
Novartis price target lowered to CHF 92 from CHF 95 at UBS
09/29/21 Stifel
Blueprint Medicines rersumed with a Hold at Stifel
09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
MKKGY Merck KGaA
$44.51 /

+1.15 (+2.65%)

09/17/21 Morgan Stanley
Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
09/13/21 Deutsche Bank
Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
09/10/21 JPMorgan
Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
09/02/21 Barclays
Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
MRTX Mirati Therapeutics
$171.89 /

-6.27 (-3.52%)

09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
09/21/21 Oppenheimer
Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer
09/07/21 JPMorgan
Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan
AMGN Amgen
$203.70 /

+1.63 (+0.81%)

10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
RVMD Revolution Medicines
$27.77 /

+0.385 (+1.41%)

09/22/21 Stifel
Revolution Medicines initiated with a Hold at Stifel
08/17/21 H.C. Wainwright
Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright
08/12/21
Fly Intel: Top five analyst downgrades
08/12/21 Guggenheim
Revolution Medicines price target lowered to $34 from $52 at Guggenheim
TPTX Turning Point Therapeutics
$47.00 /

+0.9 (+1.95%)

RVMD Revolution Medicines
$27.77 /

+0.385 (+1.41%)

RHHBY Roche
$48.22 /

-0.01 (-0.02%)

NVS Novartis
$82.47 /

+0.425 (+0.52%)

MRTX Mirati Therapeutics
$171.89 /

-6.27 (-3.52%)

AMGN Amgen
$203.70 /

+1.63 (+0.81%)

  • 04
    Feb
  • 28
    Oct
  • 27
    Oct
RHHBY Roche
$48.22 /

-0.01 (-0.02%)

NVS Novartis
$82.47 /

+0.425 (+0.52%)

RHHBY Roche
$48.22 /

-0.01 (-0.02%)

NVS Novartis
$82.47 /

+0.425 (+0.52%)

MRTX Mirati Therapeutics
$171.89 /

-6.27 (-3.52%)

AMGN Amgen
$203.70 /

+1.63 (+0.81%)

NVS Novartis
$82.47 /

+0.425 (+0.52%)

AMGN Amgen
$203.70 /

+1.63 (+0.81%)

Conference/Events
Stifel healthcare analysts to hold an analyst/industry conference call » 10:30
10/11/21
10/11
10:30
10/11/21
10:30
TPTX

Turning Point Therapeutics

$46.08 /

-1.61 (-3.38%)

, RHHBY

Roche

$49.89 /

+1.84 (+3.83%)

, NVS

Novartis

$82.95 /

+0.105 (+0.13%)

, MKKGY

Merck KGaA

$43.18 /

-0.0125 (-0.03%)

, MRTX

Mirati Therapeutics

$167.96 /

-0.275 (-0.16%)

, AMGN

Amgen

$209.50 /

+0.6 (+0.29%)

, RVMD

Revolution Medicines

$27.66 /

-0.12 (-0.43%)

Healthcare Analysts,…

Healthcare Analysts, along with Dr. David Ross Camidge and Dr. Vamsidhar Velcheti, discuss how TPTX's repotrectinib safety data might inform 1L or 2L market share in ROS1+ NSCLC, the opportunity for TPTX's TPX-022 MET inhibitor in METex14 NSCLC and Amgen's Lumakras KRAS G12C NSCLC launch on an Analyst/Industry conference call to be held on October 14 at 3 pm. Webcast Link

ShowHide Related Items >><<
TPTX Turning Point Therapeutics
$46.08 /

-1.61 (-3.38%)

RVMD Revolution Medicines
$27.66 /

-0.12 (-0.43%)

RHHBY Roche
$49.89 /

+1.84 (+3.83%)

NVS Novartis
$82.95 /

+0.105 (+0.13%)

MRTX Mirati Therapeutics
$167.96 /

-0.275 (-0.16%)

MKKGY Merck KGaA
$43.18 /

-0.0125 (-0.03%)

AMGN Amgen
$209.50 /

+0.6 (+0.29%)

TPTX Turning Point Therapeutics
$46.08 /

-1.61 (-3.38%)

10/11/21 JMP Securities
Turning Point downgraded to Market Perform from Outperform at JMP Securities
10/08/21 Roth Capital
Turning Point selloff brings 'bargain value,' says Roth Capital
10/08/21 Wedbush
Turning Point Therapeutics price target lowered to $125 from $166 at Wedbush
10/07/21 Wells Fargo
Turning Point Therapeutics price target lowered to $120 from $160 at Wells Fargo
RHHBY Roche
$49.89 /

+1.84 (+3.83%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
NVS Novartis
$82.95 /

+0.105 (+0.13%)

10/08/21 UBS
Novartis price target lowered to CHF 92 from CHF 95 at UBS
09/29/21 Stifel
Blueprint Medicines rersumed with a Hold at Stifel
09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
MKKGY Merck KGaA
$43.18 /

-0.0125 (-0.03%)

09/17/21 Morgan Stanley
Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley
09/13/21 Deutsche Bank
Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
09/10/21 JPMorgan
Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
09/02/21 Barclays
Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
MRTX Mirati Therapeutics
$167.96 /

-0.275 (-0.16%)

09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
09/21/21 Oppenheimer
Mirati Therapeutics price target raised to $175 from $160 at Oppenheimer
09/07/21 JPMorgan
Mirati Therapeutics price target lowered to $203 from $205 at JPMorgan
AMGN Amgen
$209.50 /

+0.6 (+0.29%)

10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
RVMD Revolution Medicines
$27.66 /

-0.12 (-0.43%)

09/22/21 Stifel
Revolution Medicines initiated with a Hold at Stifel
08/17/21 H.C. Wainwright
Revolution Medicines price target lowered to $31 from $55 at H.C. Wainwright
08/12/21
Fly Intel: Top five analyst downgrades
08/12/21 Guggenheim
Revolution Medicines price target lowered to $34 from $52 at Guggenheim
TPTX Turning Point Therapeutics
$46.08 /

-1.61 (-3.38%)

RVMD Revolution Medicines
$27.66 /

-0.12 (-0.43%)

RHHBY Roche
$49.89 /

+1.84 (+3.83%)

NVS Novartis
$82.95 /

+0.105 (+0.13%)

MRTX Mirati Therapeutics
$167.96 /

-0.275 (-0.16%)

AMGN Amgen
$209.50 /

+0.6 (+0.29%)

  • 04
    Feb
  • 28
    Oct
  • 27
    Oct
RHHBY Roche
$49.89 /

+1.84 (+3.83%)

NVS Novartis
$82.95 /

+0.105 (+0.13%)

RHHBY Roche
$49.89 /

+1.84 (+3.83%)

NVS Novartis
$82.95 /

+0.105 (+0.13%)

MRTX Mirati Therapeutics
$167.96 /

-0.275 (-0.16%)

AMGN Amgen
$209.50 /

+0.6 (+0.29%)

NVS Novartis
$82.95 /

+0.105 (+0.13%)

AMGN Amgen
$209.50 /

+0.6 (+0.29%)

Recommendations
Merck KGaA price target raised to EUR 200 from EUR 185 at Morgan Stanley » 12:58
09/17/21
09/17
12:58
09/17/21
12:58
MKKGY

Merck KGaA

$46.38 /

-0.45 (-0.96%)

Morgan Stanley analyst…

Morgan Stanley analyst Mark Purcell raised the firm's price target on Merck KGaA to EUR 200 from EUR 185 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
MKKGY Merck KGaA
$46.38 /

-0.45 (-0.96%)

MKKGY Merck KGaA
$46.38 /

-0.45 (-0.96%)

09/13/21 Deutsche Bank
Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank
09/10/21 JPMorgan
Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
09/02/21 Barclays
Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
08/10/21 Morgan Stanley
Merck KGaA price target raised to EUR 185 from EUR 145 at Morgan Stanley
Recommendations
Merck KGaA price target raised to EUR 240 from EUR 220 at Deutsche Bank » 15:01
09/13/21
09/13
15:01
09/13/21
15:01
MKKGY

Merck KGaA

$47.98 /

-0.87 (-1.78%)

Deutsche Bank analyst…

Deutsche Bank analyst Falko Friedrichs raised the firm's price target on Merck KGaA to EUR 240 from EUR 220 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
MKKGY Merck KGaA
$47.98 /

-0.87 (-1.78%)

MKKGY Merck KGaA
$47.98 /

-0.87 (-1.78%)

09/10/21 JPMorgan
Merck KGaA price target raised to EUR 230 from EUR 220 at JPMorgan
09/02/21 Barclays
Merck KGaA price target raised to EUR 175 from EUR 155 at Barclays
08/10/21 Morgan Stanley
Merck KGaA price target raised to EUR 185 from EUR 145 at Morgan Stanley
08/09/21 Deutsche Bank
Merck KGaA price target raised to EUR 220 from EUR 155 at Deutsche Bank

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.